Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

Novo Nordisk said on Friday it is seeking a preliminary U.S. ​court injunction to immediately block obesity ‌and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry ​between the two groups.

Reuters • 14 hours ago

Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?

Eli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy. Lilly has been winning the race to dominate the GLP-1 drug market.

The Motley Fool • 6 hours ago

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads

Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.

WSJ • 13 hours ago

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

Barrons • 10 hours ago

Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications

MCLEAN, Va.--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer health plans across the United States. Through an alternative pharmacy benefit structure, the agreement will allow Crux to deliver a dedicated carve-out solut.

Business Wire • Jul 23, 2026

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

Novo Nordisk (NVO) closed the most recent trading day at $48.19, moving 2.41% from the previous trading session.

Zacks Investment Research • Jul 22, 2026

Many US patients opt for obesity drug injections, defying some expectations

Many patients have opted for injectable forms of the wildly popular GLP-1 obesity medications through a pilot program of the U.S. government's Medicare health ​insurance program for Americans aged 65 and older, according to early indications from doctors and analysts.

Reuters • Jul 22, 2026

Hair loss with GLP-1 drugs is rare, but real, studies find

The risk ‌of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.

Reuters • Jul 22, 2026

The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side

The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried.

24/7 Wall Street • Jul 22, 2026

Weight loss drugs linked to increase risk of hair loss

Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.

Skynews • Jul 23, 2026